Altered transcriptome signature of phenotypically normal skin fibroblasts heterozygous for CDKN2A in familial melanoma: Relevance to early intervention

Oncotarget

Volumn 4, Issue 1, 2013, Pages 128-141

  Fan, Meiyun ^a   Pfeffer, Susan R ^a   Lynch, Henry T ^b   Cassidy, Pamela ^c   Leachman, Sancy ^c   Pfeffer, Lawrence M ^a   Kopelovich, Levy ^d  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CDKN2A; Familial melanoma; Gene expression; Melanoma; Mutations; p16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DOUBLE STRANDED DNA; PROTEIN P16; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CANCER RISK; CDKN2A GENE; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EARLY INTERVENTION; FAMILIAL MELANOMA; FEMALE; GENE DISRUPTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; PHENOTYPE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION; UPREGULATION;

EID: 84875797484     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.786     Document Type: Article

References (30)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012; 62(1):10-29.
2. Narayanan DL, Saladi RN and Fox JL. Ultraviolet radiation and skin cancer. International journal of dermatology. 2010; 49(9):978-986.
3. Tsao H, Chin L, Garraway LA and Fisher DE. Melanoma: from mutations to medicine. Genes Dev. 2012; 26(11):1131-1155.
4. Kefford RF, Newton Bishop JA, Bergman W and Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. J Clin Oncol. 1999; 17(10):3245-3251.
5. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000; 42(5 Pt 1):705-722; quiz 723-706.
6. Lynch HT, Fusaro RM, Lynch JF and Brand R. Pancreatic cancer and the FAMMM syndrome. Familial cancer. 2008; 7(1):103-112.
7. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, Azizi E, Bianchi-Scarra G, Bishop DT, Bressac-de Paillerets B, Bruno W, Calista D, Cannon Albright LA, Demenais F, Elder DE, Ghiorzo P, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006; 66(20):9818-9828.
8. Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ and Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Archives of dermatology. 2003; 139(8):1019-1025.
9. Qiu W, Sahin F, Iacobuzio-Donahue CA, Garcia-Carracedo D, Wang WM, Kuo CY, Chen D, Arking DE, Lowy AM, Hruban RH, Remotti HE and Su GH. Disruption of p16 and activation of Kras in pancreas increase ductal adenocarcinoma formation and metastasis in vivo. Oncotarget. 2011; 2(11):862-873.
10. Pho L, Grossman D and Leachman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Current opinion in oncology. 2006; 18(2):173-179.
11. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-263.
12. Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, Palmero I, Ryan K, Hara E, Vousden KH and Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998; 17(17):5001-5014.
13. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002; 94(12):894-903.
14. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J, Atkins D and Wang Y. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005; 11(20):7234-7242.
15. Parry D and Peters G. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma. Mol Cell Biol. 1996; 16(7):3844-3852.
16. Gordon PR, Treloar VD, Vrabel MA and Gilchrest BA. Relative responsiveness of cultured human epidermal melanocytes and melanoma cells to selected mitogens. J Invest Dermatol. 1986; 87(6):723-727.
17. Herbert BS, Chanoux RA, Liu Y, Baenziger PH, Goswami CP, McClintick JN, Edenberg HJ, Pennington RE, Lipkin SM and Kopelovich L. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. Oncotarget. 2010; 1(6):405-422.
18. Leachman SA, Carucci J, Kohlmann W, Banks KC, Asgari MM, Bergman W, Bianchi-Scarra G, Brentnall T, Bressac-de Paillerets B, Bruno W, Curiel-Lewandrowski C, de Snoo FA, Debniak T, Demierre MF, Elder D, Goldstein AM, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol. 2009; 61(4):677 e671-614.
19. Kopelovich L. Skin fibroblasts from humans predisposed to colon cancer are not abnormally sensitive to DNA damaging agents. Cell biology international reports. 1983; 7(5):369-375.
20. Koh J, Enders GH, Dynlacht BD and Harlow E. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 1995; 375(6531):506-510.
21. Walker GJ, Gabrielli BG, Castellano M and Hayward NK. Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer. 1999; 82(2):305-312.
22. Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 2000; 14(14):1712-1728.
23. Smith AP, Hoek K and Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther. 2005; 4(9):1018-1029.
24. Glondu-Lassis M, Dromard M, Lacroix-Triki M, Nirde P, Puech C, Knani D, Chalbos D and Freiss G. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res. 2010; 70(12):5116-5126.
25. Tamai H, Miyake K, Yamaguchi H, Takatori M, Dan K, Inokuchi K and Shimada T. Resistance of MLL-AFF1-positive acute lymphoblastic leukemia to tumor necrosis factor-alpha is mediated by S100A6 upregulation. Blood cancer journal. 2011; 1(11):e38.
26. Kumar R, Angelini S and Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene. 2003; 22(58):9217-9224.
27. Ulitsky I, Maron-Katz A, Shavit S, Sagir D, Linhart C, Elkon R, Tanay A, Sharan R, Shiloh Y and Shamir R. Expander: from expression microarrays to networks and functions. Nature protocols. 2010; 5(2):303-322.
28. Paz A, Brownstein Z, Ber Y, Bialik S, David E, Sagir D, Ulitsky I, Elkon R, Kimchi A, Avraham KB, Shiloh Y and Shamir R. SPIKE: a database of highly curated human signaling pathways. Nucleic Acids Res. 2011; 39(Database issue):D793-799.
29. Wei L, Sandbulte MR, Thomas PG, Webby RJ, Homayouni R and Pfeffer LM. NFκB negatively regulates interferon-induced gene expression and anti-influenza activity. J Biol Chem. 2006; 281(17):11678-11684.
30. Pfeffer LM, Kim JG, Pfeffer SR, Carrigan DJ, Baker DP, Wei L and Homayouni R. The role of NF-κB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem. 2004; 279(30):31304-31311